Imetelstat reduces RBC transfusion dependence in patients with lower-risk myelodysplastic syndromes Medha Baranwal12 Dec 2023 1:00 AM ISTUSA: An investigational, first-in-class telomerase inhibitor was shown to improve rates of red blood cell (RBC) transfusion independence in patients...
Type of Allergy medicine may have role in treatment of lung cancer Dr. Kamal Kant Kohli11 Dec 2023 9:45 AM ISTUSA: A recent study published in Nature has identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of...
Link between ultra-processed foods and cancer not explained by body fat: Study Medha Baranwal11 Dec 2023 3:00 AM ISTUK: A recent study has revealed a positive association between higher consumption of ultra-processed foods (UPF) and an increased risk of head and...
Contrast agent use not necessary in PET/MRI scans in children with lymphoma: Study Medha Baranwal10 Dec 2023 9:15 PM ISTGermany: A recent study has provided a scientific baseline for choosing F-18 FDG-PET/MRI scans without the use of a contrast agent for imaging...
Merck announces positive results from phase 2 trial evaluating coformulation of vibostolimab, pembrolizumab in lung cancer patients Ruchika Sharma10 Dec 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced full results from the non-registrational Phase 2 KeyVibe-002...
Sanofi multiple myeloma drug Sarclisa phase 3 trial meets primary endpoint of progression-free survival Ruchika Sharma10 Dec 2023 11:30 AM ISTParis: Sanofi has announced that the Phase 3 IMROZ trial evaluating the investigational use of Sarclisa (isatuximab) in combination with...
Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial Ruchika Sharma9 Dec 2023 1:30 PM ISTRahway: Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line...
Pfizer Elrexfio gets European Commission approval for Multiple Myeloma Ruchika Sharma9 Dec 2023 12:00 PM ISTThe conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
Use of GLP-1 drugs in type 2 diabetes tied to reduced risk of colorectal cancer: JAMA Medha Baranwal9 Dec 2023 11:30 AM ISTUSA: A nationwide cohort study revealed a greater reduction in the risk of colorectal cancer (CRC) with the use of glucagon-like peptide 1 (GLP-1)...
Merck to stop phase 3 trial of Keytruda plus Lynparza for lung cancer patients Ruchika Sharma8 Dec 2023 3:19 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating...
Bristol Myers Squibb Abecma approved for use in earlier lines of therapy for patients with relapsed or refractory Multiple Myeloma in Japan Ruchika Sharma7 Dec 2023 4:30 PM ISTTokyo: Bristol-Myers Squibb K.K. has announced that the company has received manufacturing and marketing approval of the supplemental New Drug...
USFDA accepts for priority review Bristol Myers Squibb application for Opdivo plus Cisplatin-Based Chemotherapy for urothelial carcinoma Ruchika Sharma7 Dec 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
